IMVT-1402 bets on FcRn blockade across RA, MG, and Graves disease after batoclimab's Phase 3 TED failure resets the entire investment case

Immunovant is a clinical-stage company developing a targeted immune therapy to reduce pathogenic immune proteins for rheumatoid arthritis, myasthenia gravis, and Graves disease, none of which is yet approved with this drug.

IMVT-1402, an FcRn inhibitor targeting pathogenic IgG reduction, is in potentially registrational trials for difficult-to-treat RA, myasthenia gravis, and Graves disease. The thesis resolves on whether randomized D2T RA and MG topline data in 2026-2027 replicate the open-label ACR20/50/70 signals with statistical significance. Efgartigimod (argenx) and rozanolixizumab (UCB) are already approved FcRn inhibitors in MG and hold first-mover advantage in physician adoption.